D-0938-2023 Class I Terminated

Recalled by Cipla USA, Inc. — Warren, NJ

FDA drug recall D-0938-2023 was initiated by Cipla USA, Inc. on Jun 27, 2023 and is designated Class I. Reason for recall: Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket). The recall status is terminated (terminated Mar 6, 2025). Affected quantity: 278,538 canisters.

Recall details

Product Type
Drugs
Report Date
Jul 19, 2023
Initiation Date
Jun 27, 2023
Termination Date
Mar 6, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
278,538 canisters

Product description

Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 Metered Inhalation, net content 6.7 g canister packaged in a box, Rx only, Manufactured by: Cipla Ltd, Indore SE Z, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ, 07059, NDC 69097-142-60

Reason for recall

Defective container: empty inhaler and leakage observed through the inhaler valve due to partially missing bottom seat (gasket).

Distribution pattern

Nationwide in the US

Code information

Lot # IB20045, IB20055, IB20056, IB20057, IB20059, IB20072, Exp Nov. 30, 2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0938-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0938-2023. Report a data issue: hello@regdatalab.com.